Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 3/20 | 0.45 |
| ▸ | ITGB3 | P05106 | 12/20 | 0.44 |
| ▸ | ITGAV | P06756 | 3/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | CPA1 | P15085 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7034103 | 0.91 | ITGB3 (0.46) | TGM2ITGB3ITGAVITGA2BEGLN2 | |
| SCHEMBL7034815 | 0.90 | ITGB3 (0.53) | ITGB3ITGAVITGA2BEGLN2EGLN1 | |
| SCHEMBL7037146 | 0.90 | ITGB3 (0.46) | ITGB3ITGAVITGA2BEGLN2EGLN1 | |
| SCHEMBL7037166 | 0.85 | PLAU (0.43) | ITGB3ITGAVITGA2BEGLN2EGLN1 | |
| SCHEMBL7031295 | 0.84 | ITGB3 (0.40) | ITGB3ITGAVITGA2BEGLN2EGLN1 | |
| SCHEMBL7036039 | 0.84 | ITGB3 (0.40) | ITGB3ITGAVITGA2BEGLN2EGLN1 | |
| SCHEMBL7038291 | 0.84 | ITGB3 (0.41) | ITGB3ITGAVITGA2BEGLN2EGLN1 | |
| SCHEMBL7030722 | 0.84 | F10 (0.40) | ITGB3ITGAVITGA2BEGLN2EGLN1 | |
| SCHEMBL7035668 | 0.83 | ITGB3 (0.43) | ITGB3ITGAVITGA2B | |
| SCHEMBL7255333 | 0.83 | F10 (0.40) | ITGB3ITGAVITGA2BEGLN2EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | claimed |
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | AMERICAN HOME PRODUCTS CORPORATION (US) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186967-A1 | Acylresorcinol derivatives are selective vitronectin receptor inhibitors | ASGR1, TEK, APLNR | TGM2 2301/4885ITGB3 403/4885ITGAV 289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.